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ABSTRACT 
THE EFFECT OF BASAL BOLUS INSULIN ADMINISTRATION VS. SLIDING 
SCALE INSULIN ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 
DIABETES MELLITUS AT A COMMUNITY HOSPITAL 
 
Evidence of effective insulin delivery by nurses can help prevent fluctuating 
plasma glucose levels of Type 2 diabetes mellitus (T2DM) in the hospital setting. 
Information  leading to better diabetes care using either basal bolus insulin administration 
(BBI) or sliding scale insulin (SSI) is essential for safe blood sugar values. The purpose 
of this project was to measure patient glycemic control after the implementation of BBI 
vs. SSI during a patients’ stay in the hospital. This study was a quantitative, retrospective 
exploratory chart review of T2DM in medical-surgical units at a Northern California 
community hospital. The data were collected from routine standardized point of care 
testing documentation on an electronic record. The study timeframe of chart reviews 
occurred from May 2017 to May 2018. Results suggest that SSI provided better glycemic 
control in hospitalized patients with T2DM. This study showed when using SSI, the 
average blood glucose was lower and that the estimated mean HgbA1c was lower in 
comparison to BBI. 
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CHAPTER 1: INTRODUCTION 
Diabetes mellitus is a life-threatening disease with chronic long-term 
complications affecting over 30 million people (Centers for Disease Control and 
Prevention [CDC], 2017). Ninety-five percent of individuals with diabetes are 
diagnosed with type 2 diabetes mellitus (T2DM) and 5% have type 1 diabetes. In 
2015, diabetes became the seventh leading cause of death and the cost of the 
disease in the United States was estimated at $245 billion (CDC, 2017). 
Controlling insulin levels for diabetes is more challenging when patients are in the 
hospital; insulin needs increase during acute illness or surgery because of the 
physiological stress in the human body (Johnson & Van Horn, 2011). Ensuring 
better glycemic control in T2DM is paramount to long-term survival. 
Problem Statement 
After the implementation of Basal Bolus Insulin Administration (BBI) 
guidelines at a Northern California community hospital, concerns were raised if 
BBI would have better glycemic control in patients with T2DM than Sliding Scale 
Insulin (SSI). In 2016, the American Diabetes Association (ADA) strongly 
discouraged only the use of sliding scale insulin in patients with T2DM. Instead, a 
basal plus bolus correction insulin regimen was the preferred treatment (ADA, 
2016). Although several researchers examined the management of T2DM patients 
in the hospital setting, data on glycemic control has been difficult to record and 
track for BBI vs. SSI at a Northern California community hospital. There has been 
minimal research comparing  glycemic control between patients managed with 
BBI and SSI within the same hospital setting. The aim of this research was to 
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retrospectively review blood sugar readings between T2DM patients managed 
with either BBI vs. SSI. 
Purpose 
The purpose of the study was to assess glycemic control following the 
implementation of BBI as compared to SSI for hospitalized patients with T2DM at 
a community hospital. 
Background 
Diabetes is a metabolic disease characterized by abnormal insulin secretion. 
Type 2 diabetes mellitus (T2DM) is characterized by insufficient insulin 
production. According to the American Diabetes Association (2014), T2DM 
patients have an impaired and defective insulin secretion and response.  
Basal bolus insulin administration (BBI) has been defined as when a patient 
receives a long-acting insulin and a short-acting insulin to minimize abnormal 
blood glucose levels (Umpierrez et al., 2007). For example, a patient would 
receive a daily long-acting insulin and before meals rapid-acting insulin analogs 
(Umpierrez et al., 2007). One disadvantage would be daily multiple injections. 
Evidence suggests that using BBI improves glucose control, decreases hospital 
complications, and reduces the length of stay. Umpierrez et al. (2011) found that 
the application of basal-bolus insulin to T2DM patients after surgery and to non-
critically ill patients showed better management of diabetes than sliding scale 
insulin (SSI), a method discovered in the late 1970s for short-term use in the 
hospital that was "never associated with improved clinical outcomes" (Umpierrez 
et al., 2007, p. 2185). Basal-bolus insulin showed improvement in managing 
diabetes, specifically by preventing hyperglycemia while patients were in the 
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hospital (Umpierrez et al., 2011) and decreasing complications associated with 
diabetes (Harris, Narayan, & Ali, 2015). 
On the other hand, sliding scale insulin (SSI) is the oldest form in the 
treatment of diabetes. In the sliding scale insulin method, the dose is based upon 
the blood sugar level just before the next meal. The amount of insulin is listed in a 
chart. It is based on the progression of increasing the rapid-acting or regular 
insulin with the addition of scheduled insulin injections to sustain blood glucose 
levels if required. The major disadvantages of using a sliding scale are that meals 
should contain the same amount of carbs. In the hospital setting, meals may be 
regulated by carbohydrate counts, but withholding food, changes in activity and 
stress will also affect blood glucose levels. Despite disadvantages, this treatment is 
commonly used in the hospital setting (Alfehaid, Alotaibi, Alanazi, Bustami, & El 
Malik, 2018).  The principal difference between the two strategies is that sliding-
scale insulin does not deliver adequate glycemic control to patients and addresses 
hyperglycemia after it has occurred, whereas a basal–bolus regimen is directed at 
preventing hyperglycemia (Badlani et al., 2014). 
Glycemic control was defined by the American Diabetes Association’s 
(ADA, 2018) official recommendations for people with diabetes—namely, (1) 
fasting glucose is 80–130 mg/dL (4.4-7.2 mmol/L) and (2) 2 hours after meals it is 
less than 180mg/dL (10.0mmol/L). Hypoglycemia was defined as follows: 
Level 1: A glucose alert value of 3.9 mmol/l (70 mg/dl) or less.  
Level 2: A glucose level of <3.0 mmol/l (<54 mg/dl) is sufficiently low to 
indicate serious, clinically important hypoglycemia. 
Level 3: Severe hypoglycemia, as defined by the American Diabetes 
Association (2018) denotes severe cognitive impairment requiring external 
assistance for recovery. 
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Glycemic control is important to the patient, nurses, and the hospital for 
various reasons. For the patient, good glycemic control with proper insulin 
treatment minimizes microvascular complications, decrease cardiovascular 
complications, and all-cause mortality. For the purpose of this study, 
hypoglycemia was measured based on blood glucose levels less than 70 mg/dL 
(American Diabetes Association, 2014). Lower blood glucose levels are often not 
reported as much as higher blood glucose levels. It is important to have glycemic 
control for T2DM patients to prevent microvascular and cardiovascular 
complications and to decrease all-cause mortality (Elliott, Fidler, Ditchfield, & 
Stissing, 2016). The most common feared adverse effect of diabetes insulin 
therapy management is hypoglycemia. It is through proper management of 
treatment modality to achieve good glycemic control ((Elliott et al., 2016). 
Point-of-care testing (POCT) is defined as diagnostic type of test done at 
the patient’s bedside and considered as a way to provide quick information about 
the patient’s blood glucose levels (Klonoff, 2014). The recommended general 
glycemic target is a glycated hemoglobin (HbA1c) level of <7 mg/dL (American 
Diabetes Association, 2016). The estimated glycated hemoglobin (eAG) is a new 
recommended term from the American Diabetes Association, this allowed 
reporting of HbA1c results for diabetes patients, utilized same units (mg/dL or 
mmol/L in day-to-day blood glucose measurements (American Diabetes 
Association, n.d.). 
Significance for Nurses 
Nurses specializing in diabetes are key members of the inpatient care team 
for the translation of research related to evidence-based diabetes practice. In May 
2016, a Northern California community hospital conducted a study to understand 
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nurses’ baseline diabetes patient care knowledge prior to making a treatment 
change to BBI. Results showed that continued emphasis to improve and sustain 
nursing knowledge on basal-bolus insulin therapy was necessary. 
Recommendations included a larger enterprise-wide education program to 
introduce basal-bolus insulin therapy as an ongoing educational opportunity in 
order to sustain nursing knowledge gains and improve confidence levels. 
In addition to providing this evidence, nurse practitioners specializing in 
diabetes should be included on committees that write institutional guidelines and 
policy on when and how to initiate and change/adjust insulin therapy. The clinical 
management of T2DM patients in the medical-surgical units is important to the 
hospital. The importance of glycemic control during the patients’ hospital stay 
improves patients’ care outcomes, decreases mortality and morbidity rates, and 
decreases readmissions and length of stay. Patients recover from their medical 
illness and surgical patients experience better healing in surgical patients. 
The Centers for Medicare and Medicaid Services (CMS) has been working 
on improving quality care. CMS will focus on healthcare of Medicare 
beneficiaries, and the quality measures that were helpful for quantifying processes, 
outcomes, and patient perceptions. Recently, CMS developed a new way of 
identifying and prioritizing measures called “Meaningful Measures” (National 
Quality Forum [NQF], n.d.). The focus was to develop new medication measures 
with the chance of being validated by the National Quality Forum (NQF), an 
organization aimed at evaluating and supporting standardized performance 
measurement. Two of the Hospital Inpatient Quality Reporting (IQR) with clinical 
quality measures involve inpatients: (a) the NQF 2362, which is glycemic control–
hyperglycemia and (b) NQF 2363, which is glycemic control–severe 
hypoglycemia (NQF, n.d.). 
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Another goal of conducting this project was to contribute to quality 
improvement of the NQF performance standards within a Northern California 
community hospital organization. By applying measure NQF 2363, the metrics of 
the BBI and SSI were measured. The goal would be to raise awareness about 
providing high-quality care for T2DM patients reporting glycemic control while 
hospitalized. 
Theoretical Framework 
The implementation of BBI in a community hospital setting involves 
multiple layers of systems. In fact, the use of BBI was a patient care outcome 
project related to quality improvement initiatives. The investigator used two 
theories for studying this phenomenon: (a) general systems theory by Ludwig von 
Bertalanffy (1972) and (b) complexity theory, which was based on general 
systems theory (Skyttner, 2006). 
Complexity theory sees the organization as the system and the subsystems 
and their interactions with the processes, outcomes, and foreseeable and 
unforeseeable consequences that may occur over time (Chandler, Rycroft-Malone, 
Hawkes, & Noyes, 2015). According to Johnson (2011), complexity theory 
explains how the behavior of the whole, rather than its parts, result in complex 
behaviors. He defined the theory as “the study of phenomena which emerge from a 
collection of interacting objects” (section 1.1). Based on this concept, 
communication between systems and subsystems is crucial when dealing with any 
changes in clinical practices that involve patients. The advantage of complexity 
theory is that it brings people together, generate debate on ideas, and develop a 
framework designed to explain the organization’s changes. This approach involves 
engaging disciplines when a new “attractor” is introduced and how the behaviors 
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of those affected are acknowledged. Tuffin (2016) mentioned how vital it is to 
collaborate rather than imposing top-down leadership. It is essential to provide 
sufficient feedback and allow agreeable solutions within the organization. 
It is often a challenge to convince clinicians to use a new model of care that 
is evidence-based practice. The complexity theory assumes that any actions 
performed are best accomplished by working on the barriers as a cohesive group. 
According to Litaker et al. (2006), the group needs to consider the general 
application of the clinical practice as well as its effectiveness in guiding care 
management in addition to recognizing different perspectives. Interdisciplinary 
relationship sessions are recommended, such as performing the assessment of the 
application, identifying the domains, and building methods together. 
According to Cooper and Geyer (2009), although diabetes has been known 
as a complex disease, few clinicians focus on using a theoretical framework to 
guide practice. Complexity theory has been criticized and considered as an “all-
inclusive nature of complexity seeing it as an intangible theory that fails to offer 
new [ideas] to health care” (Cooper, 2009, p. 761). Some clinicians acknowledge 
that the use of the old methodology in managing complex diseases failed because 
a theoretical framework was not used and the interaction within the system was 
not addressed. Based on two separate studies done by The Action to Control 
Cardiovascular Risk in Diabetes Study Group (2008) and van der Steeg et al. 
(2008), low glucose levels in high-risk T2DM patients were not recognized, 
placing the diabetes population at greater risk of developing coronary artery 
disease. The emergent results revealed the consequences of failing to recognize the 
harmful effects of poor glycemic control. If complexity theory had been used, this 
could have been prevented. Complexity theory allows for unpredictability and 
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uncertainty and it permits learning and discovery within the system, thereby 
enabling complexity thinking to occur (Cooper & Geyer, 2009). 
What is important to know is that the critical system’s “attractors” are 
important stakeholders who should be engaged at the start of the assessment and 
throughout the evaluation phase. Complexity theory allows for unpredictability. 
Using complexity theory allows the clinical practice and the theory to come 
together, resulting in more significant outcomes, such as the prevention of 
hyperglycemic and hypoglycemic events during patients’ hospital stay. BBI 
requires constant evaluation to ensure that the process would be practical and 
realistic in the system. 
Aim of Study 
The aim of the project was to assess glycemic control following BBI in 
comparison to SSI in the management of T2DM in hospitalized patients. 
Hypothesis 
The hypothesis was that there is a significant relationship between BBI vs. 
SSI for glycemic control in hospitalized patients with T2DM.   
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CHAPTER 2: LITERATURE REVIEW 
A literature review was undertaken to examine the efficacy of BBI and SSI 
in the management of hospitalized T2DM patients. The investigator searched 
databases for relevant literature on: T2DM, glycemic control, hypoglycemia, 
hyperglycemia, insulin therapy, basal-bolus and sliding scale.  First, research on 
T2DM relevant to the effects of insulin therapy were examined. Second, studies 
that involved insulin therapy provided to T2DM patients in a hospital setting were 
reviewed. Third, the investigator focused on the use of BBI compared to SSI. Four 
studies were selected (Fahim et al., 2015; Roberts & Godbole, 2015; Rymaszewski 
& Breakwell, 2013; Umpierrez et al., 2013). 
Fahim et al. (2015) conducted a prospective multiphase study to assess 
newly conducted BBI dosing guidelines in the medical unit before implementing 
BBI hospital-wide. The dosing guidelines were designed to check the blood 
glucose (BG) levels of patients with T2DM then compare BG before and after 
receiving BBI. The four phases of the study were as follows: (a) review of BBI 
guidelines nationwide; (2) conduct multidisciplinary clinical staff education on the 
dosing guidelines; (3) enroll 43 patients in the pilot study; and (4) conduct data 
analysis using chi-square for categorical variables, paired t-test for continuous 
variables, and descriptive statistics for determining demographics. Results 
indicated that the total BG was 377 mg/dl values before the use of dosing 
guidelines and 723 mg/dl values after. 
Fahim et al. (2015) noted a statistically significant difference in the BG 
parameters between pre and post BBI at the end points; the pre BBI was p < 0.5 
and the post BBI was p < 0.05. There was no occurrence of diabetic ketoacidosis 
or hyperosmolar hyperglycemic states. The authors revised the insulin dosing 
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guideline parameters and the units per kilogram and nurses provided insulin 
administration based on the dosing guidelines. The strength of the study was the 
multiphase approach, which identified the BG guidelines needed to be changed 
based on the results of the pilot phase. Conclusions supported having all 
physicians adjusting insulin doses based on the BBI guidelines. 
Roberts and Godbole (2015) also conducted a retrospective and prospective 
chart review to identify the accuracy of BBI and SSI dosing administration in a 
tertiary teaching hospital. The retrospective chart review was done for the SSI and 
a prospective chart review for the BBI. The sample population was 46 diabetic 
inpatients with less than 5 days of receiving BBI. Investigators only studied and 
analyzed insulin given at 0700, 1200, and 1700. The 2100 hours insulin 
administration blood glucose levels were not analyzed because it will be gone by 
the next blood glucose check at 0700. The intervention was as follows: (1) the BBI 
chart was used to document blood glucose levels and had detailed information of 
the ordered insulin dosages; and (2) the SSI protocol was in the patient medication 
administration record, which required the nurses to document the blood glucose in 
different forms. 
Roberts and Godbole (2015) used a chi-square to measure the correlation of 
the doses that were not given and t tests to correlate the results. Results showed 
more missed SSI doses than BBI, and 41 missed doses (61.3%) of SSI as 
compared to the 12 medication doses of BBI (p < .001). The SSI missed doses 
mainly pertained to the group at 2100, while the BBI was 0700, 1200, 1700, and 
2100-hour times. They found that low doses of SSI (8.7%) and BBI (8.8%) was 
almost the same at p = .96). SSI patients (2.3%) received higher medication doses 
as compared to BBI patients (p = .004). The limitation of the study was the 
retrospective chart review; it did not provide a full data capture on missed doses, 
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uncertain if missed, documentation or no medication available. The strength of 
this study was the use of BBI regimen format in the workflow making it easier to 
identify missed doses in one sheet as compared to SSI where separate sheets were 
required to document blood glucose levels and the insulin medications. 
A classic retrospective chart review conducted by Rymaszewski and 
Breakwell (2013), the differences between the BBI and SSI were investigated 
using a convenience sample of 128 T2DM in-patients who were between 18-80 
years old in the medical units at a teaching hospital. They reviewed BBI and SSI 
regimens of patients who did not eat, abnormal glucose levels in the blood, length 
of stay (LOS) and events of hypoglycemia. Patients were excluded if they received 
steroids, were on oral diabetic medications or intravenous insulin, had surgery, or 
were in the hospital for less than 3 days. There were three goals in this study. The 
first goal was to determine the significant difference in blood glucose levels 
between BBI and SSI on fasting, mean and discharge. The difference was 
supported by the fasting blood glucose values, which showed SSI were higher than 
BBI (SSI 201.4; BBI 135.5; p <.001), the mean blood glucose values were higher 
in SSI than BBI (SSI 225; BBI 149; p,.001), and the discharge blood glucose 
values of SSI were also higher than BBI (SSI 244.3; BBI 128.6; p<.001). There 
were no statistically significant difference on fasting, mean, and discharge blood 
glucose values. The second goal was to investigate the association of BBI and SSI 
patients and their LOS. The LOS for SSI was 4.6 days while the BBI was 4.8 
days; the results were not statistically significant. The third goal was to determine 
if there were statistically significant differences between SSI and BBI on episodes 
of hypoglycemia (mild, moderate, or severe). Hypoglycemia was defined as blood 
glucose not lower than 70mg/dl or 389 mmol/l. The results were not statistically 
significant. The strength of the study was the results that indicated the SSI group 
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had higher fasting, mean and discharge blood glucose values in comparison to the 
BBI group.  
In another classic study, Umpierrez et al. (2013) looked at T2DM patients 
using BBI and basal plus bolus in a six-hospital multicenter organization on the 
East Coast. They enrolled 735 adult patients from the medical-surgical units using 
the following criteria: (a) patients with blood glucose between 140 and 400 mg/dl 
and (b) history of T2DM more than 3 months. The study included two outcome 
measures to identify the differences in blood glucose levels of patients treated with 
BBI, basal plus bolus, and SSI. Investigators compared the baseline of clinical 
characteristics and used the Wilcoxon test to compare continuous variables and 
chi-squares for distinct variables. Umpierrez et al. determined that there were no 
significant differences among groups in terms of age, ethnicity, body mass index, 
or length of stay in the hospital. The results revealed improved blood glucose 
control and fewer treatment errors in BBI and basal plus bolus as compared to the 
SSI group. A limitation of the study was that it did not distinguish among the six 
hospitals. The strength of this study was to show better glycemic control in 
hospitalized patients receiving BBI and basal plus bolus as compared to SSI. This 
project informed the ADA’s (2016) decision to strongly discourage only the use of 
sliding scale insulin only in patients with T2DM. 
Several studies demonstrated the clinical benefits (Fahim et al., 2015) and 
better glycemic control of using BBI over SSI (Roberts & Godbole, 2015; 
Rymaszewski & Breakwell, 2013; Umpierrez et al., 2013). For example, the SSI 
patients who missed their insulin doses or received higher medication doses had 
more severe hyperglycemic events (Umpierrez et al., 2013). The aim of this study 
was to contribute to the literature of evidence-based practice on the positive 
clinical outcomes of hospitalized patient glycemic control. 
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CHAPTER 3: METHODOLOGY 
Research Design 
The study was a descriptive quantitative chart review within a community 
hospital organization.  The design was a retrospective closed case review.  This 
study was cross-sectional with data obtained from electronic medical records from 
May 2017 to May 2018. 
Setting 
The study was conducted in a Northern California community-based 
hospital. The majority of the population is upper middle class and well educated. 
The hospital serves an ethnically diverse population. The setting was multi-site as 
there were two medical-surgical units at the same organization. The rationale for 
choosing two campuses was due to the difference in the average number of 
patients at each campus. One-unit averaged 16 patients per day and one-unit 
averaged 80 patients per day. The hospital was familiar with the basal bolus 
insulin recommendations from the ADA. 
Sample 
Inpatient electronic medical records of adult male and female patients with 
T2DM were analyzed for glycemic control. The sample included 40 electronic 
records for BBI and 50 electronic records for SSI patients conducted as a 
retrospective closed medical chart review. The inclusion criteria were as follows: 
(a) adult patients with known T2DM on admission, (b) T2DM patients who 
received SSI, (c) T2DM patients who received BBI, and (d) T2DM patients with 
the length of stay (LOS) of fewer than 5 days discharged from medical-surgical 
units. The exclusion criteria were as follows: (a) deceased T2DM patients, (b) 
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patients with gestational diabetes, (c) pediatric populations, (d) Type 1 diabetes 
mellitus patients, and (e) T2DM patients who were on observation status less than 
24 hours stay. The sources were obtained from review of medical records as part 
of a retrospective chart review (T2DM patients using ICD 10 codes, filtered by 
discharged units, BBI and SSI). The SSI and the BBI groups were based on 
medications given to T2DM patients.  
Ethical Considerations 
Patients were de-identified and coded for T2DM who received either BBI 
or SSI. The data were stored in a protected electronic folder that was password 
accessible only; the investigator was the only person that could access the data. 
After 1 year, the medical record numbers (MRN) and the coded numbers in the 
spreadsheet and all data collection sheets were destroyed. 
Procedures 
The Institutional Review Board (IRB) at California State University, 
Fresno, School of Nursing Research Committee and the El Camino Hospital IRB 
approved this project. A quantitative chart review was conducted on T2DM 
patients receiving either BBI or SSI and admitted between May 2017 and May 
2018. An information technology specialist reviewed electronic medical records a 
de-identified the data abstracted by coding.  Data were not subject to 
manipulation. 
Inclusion and exclusion criteria were applied. Electronic medical records 
were filtered for a diagnosis of T2DM base on ICD-10 codes. Next, the subjects 
who (a) received sliding scale insulin and basal bolus insulin or (b) obtained 
plasma blood glucose values from point-of-care testing with glucometer from 
 15 15 
medical surgical locations were entered onto an electronic spreadsheet. The SSI 
and the BBI groups were determined on the medications given to T2DM patients. 
The SSI group selected should be in SSI only sliding scale in the medical record 
administration (MAR) but for the purpose of the project should not have received 
any long-acting insulin. Whereas BBI would have had both. Those who received 
both BBI (with long-acting insulin) and SSI during the same admission were 
excluded and did not contribute to either group.  
The subjects’ age in years, gender and length of stay were noted and 
entered onto an electronic spreadsheet. Point-of-care blood glucose readings were 
recorded and examined for glycemic control. Finally, blood glucose readings were 
averaged for the subject’s length of stay.  
Data Analysis Plan 
De-identified data were collected and transferred to an electronic 
spreadsheet and then imported into an electronic statistical package. Data were 
analyzed using descriptive statistics. Descriptive statistics provide brief 
observations and summaries about the sample that help identify patterns (Conner 
& Johnson, 2017). An independent samples t test was used to determine age 
differences as well as length of stay between the SSI and BBI groups. A chi 
squared test of association was used to determine if there were gender differences 
between the SSI and BBI groups. 
Point-of-care testing glucose values were averaged by readings obtained 
during the subject’s length of stay. An estimated hemoglobin A1c was calculated 
based on the average glucose value. The A1c-Derived Average Glucose (ADAG) 
Study Group (2008) proposed the relationship between A1C and eAG is described 
by the formula 28.7 X A1c – 46.7 = eAG (Nathan, et al., 2008). 
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An independent samples t test was used to analyze the average blood 
glucose and estimated HbA1c among the SSI and BBI groups. The level of 
statistical significance for this project was p ≤ .05. 
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CHAPTER 4: RESULTS 
Statistical Analysis 
A total of 90 electronic medical records were selected for the study based 
on inclusion and exclusion criteria. Electronic medical records were then divided 
into two insulin administration groups: BBI and SSI. Demographic variables of 
age, gender and length of stay were compared between the two groups.  
For the entire sample, the average age was 63.66 years (SD = 15.15 years) 
and ranged from 24 years to 94 years. The average length of stay was 6.73 days 
(SD = 9.71) and ranged from 0 to 55 days (see Table 1).  
Table 1 
Descriptive Statistics for Age and Length of Stay for the Entire Sample 
Variable N Minimum Maximum M SD 
Age  90 24 94 63.66 15.51 
Length of Stay 90 0 55 6.73 9.71 
The variables of age and length of stay did not differ between the BBI and 
SSI groups (see Table 2). By group, the mean age of the BBI sample was 62.85 
(minimum age =24, maximum age = 94). The mean age of the SSI sample was 
64.30 (minimum age = 24, maximum age = 92). As determined by an independent 
samples t test, the difference in the average age of 1.45 years between the SSI and 
BBI group was not statistically significant (t(88) = -0.43, p = .66). By group, the 
mean length of stay for the BBI sample was 7.98 days with a minimum stay of 0 
days and a maximum stay of 55 days. The mean length of stay for the SSI sample 
was 5.80 days with a minimum stay of 0 days and a maximum stay of 38 days. As 
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determined by an independent sample t test, the difference of 2.10 days in the 
average stay between the SSI and BBI group was not statistically significant (t(88) 
= 1.01, p = .31). 
Table 2 
Descriptive Statistics for Age and Length of  Stay by Group 
 BBI  SSI 
Variable N Min Max M SD  N Min Max M SD 
Age  40 24 94 62.85 15.75  50 24 92 64.30 15.45 
Length of Stay 40 0 55 7.90 10.85  50 0 38 5.80 8.71 
For the entire sample, the subjects’ gender was 51.1% (n = 46) males and 
48.9% females (n = 44); 44.4% (n = 40) assigned to the BBI group and 55.6% (n = 
50) assigned to the SSI group (see Table 3). 
Table 3 
Frequencies and Percentages of Gender for the Entire Sample 
Demographic Variables  n % 
Gender   
Men 46 51.1 
Women 44 48.9 
Total 90 100.0 
Group   
BBI 40 44.4 
SSI 50 55.6 
Total 90 100.0 
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Table 4 showed the BBI sample was composed of 50% women (n = 20) and 
50% men (n = 20). The SSI sample was composed of 48% women (n = 24) and 
52% males (n = 26). As determined by a chi square test of association, there were 
no statistically significant differences in gender between the SSI and BBI group 
(x2(1) = 0.03, p = .85. 
Table 4 
Frequencies and Percentages of Gender by Group 
 BBI SSI 
Demographic Variable n (%) n (%) 
Gender   
Men 20 (50.0) 26 (52.0) 
Women 20 (50.0) 24 (48.0) 
Total 40 (100.0) 50 (100.0) 
 
There were no statistically significant differences in age, gender and length of 
stay between the BBI and the SSI groups. 
Average Blood Glucose 
An independent-samples t test was conducted to compare average blood glucose 
between the BBI and SSI groups. There was a statistically significant difference of 27.20 
mg/dL in average BG for patient between the SSI (M = 175.09, SD = 40.56) group and 
the BBI (M = 201.12, SD = 61.82) group, t(86) = 2.46, p = .01. There was a higher 
average blood glucose level for those in the BBI group as compared to those in the SSI 
group (see Table 5). 
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Estimated Hemoglobin A1c 
An independent-samples t test was conducted to compare estimated hemoglobin 
A1c blood glucose between the BBI and SSI groups. There was a statistically significant 
difference of 1.03 % found between estimated HbA1c between the BBI group (M = 8.76, 
SD = 2.10) and the SSI group (M = 7.72, SD = 1.41); t (86) = 2.76, p = .007.  These 
results suggest a higher average estimated HbA1c for those in the BBI group as compared 
to the SSI group (see Table 5). 
Table 5 
Independent Samples t Tests for Averages Blood Glucose and Estimated HbA1c 
Variable Instruction  N M SD t P Mean 
Difference 
95% CI 
(Lower, 
Upper) 
Average 
BG 
BBI  39 202.12 61.82 2.46 .01 27.02 5.24, 48.11 
  SSI 49 175.09 40.56 
 
  
Estimated 
HbA1c 
BBI  39 8.76 2.10 2.76 .007 1.03 0.29, 1.78 
  SSI 49 7.72 1.41     
Note. p = .007 
Results suggest that SSI provides better glycemic control. Specifically, 
results suggest that when using SSI, the average blood glucose is lower (see Figure 
1) and the estimated HbA1c is lower (see Figure 2) during the subjects stay in the 
hospital. 
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Figure 1. Average blood glucose level mg/dL comparing basal bolus insulin (BBI) 
to sliding scale insulin (SSI). 
Figure 2. Estimated HbA1c comparing basal bolus insulin (BBI) to sliding scale 
insulin (SSI) 
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CHAPTER 5: DISCUSSION 
This project had many similarities and differences with prior investigations. 
Between the BBI and SSI groups there were no demographic variable differences 
between hospitalized patients in this study. In other words, there were no statistical 
differences between groups as related to age, gender and length of stay which was 
similar to other literature reviews of Rymaszewski & Breakwell, 2013, and 
Umpierrez et al., 2013. 
In comparison of the average blood glucose of the two groups, this study 
revealed that the SSI group showed a lower average blood glucose than the BBI 
group. This is contrary to several studies which demonstrated the clinical benefits 
(Fahim et al., 2015) and better glycemic control of using BBI over SSI (Roberts & 
Godbole, 2015; Rymaszewski & Breakwell, 2013; Umpierrez et al., 2013). In fact, 
Umpierrez et al., 2013 found that SSI patients who missed their insulin doses or 
received higher medication doses had more statistically significant hyperglycemic 
events (Umpierrez et al., 2013). 
Although the researcher was not able to determine the hypoglycemic events 
in this study, Rymaszewski and Breakwell (2013) studied the effectiveness of 
glycemic control with SSI and BBI and found more episodes of mild/moderate 
hypoglycemic with BBI than SSI therapy, although the difference was not 
statistically significant. Roberts and Godbole (2015) performed a retrospective 
chart review of SSI and a prospective chart review of BBI. In the SSI retrospective 
study, low doses of SSI and BBI were almost the same whereas the SSI group 
received higher doses of medications than the BBI group. 
In comparison with the HbA1c, a statistically significant difference 
emerged, suggesting a lower average estimated HgbA1c for those in the SSI group 
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as compared to the BBI group. In comparison with Rymaaszweski & Breakwell 
(2013) study showed HbA1c were not different in BBI and SSI with questionable 
accuracy in their HbA1c values reported. 
Elliott et al. (2016) found that it is also important to use HbA1c as platform 
targets to understand higher hypoglycemic event rates because patients might 
present with no symptoms, patients and nurses might not notice no symptoms, and 
they might underreport events. The study outcomes, which were consistent with 
Elliott et al.’s (2016) findings, indicated that the retrospective chart review could 
likely underestimate the real incidence of glycemic control, as compared with the 
prospective study. The results showed that healthcare professionals did not report 
lower blood glucose levels as often as higher blood glucose levels (Elliott et al., 
2016). Elliot et al.’s (2016) study results revealed the opposite of the stated aim 
which was to compare the low BG events versus those who are reported in clinical 
trials. The researchers examined the possibility and why it occurred that way. 
Elliott et al. (2016) further mentioned that real-world data versus randomized 
controlled trials (RCTs) can guide healthcare professionals in providing proper 
management and treatment of choice to achieve glycemic control. 
There could be two possible implications in this study for health care 
providers. First, whether SSI or BBI order sets were used, clinicians need to 
consider what type of insulin management appropriate for their patients, 
individualized care based on the patient’s glycemic blood levels and presenting 
signs and symptoms, looking at the patient’s overall diagnosis. Another 
implications ,which was not part of this study, to consider clinicians familiarity 
with SSI and BBI protocols. 
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Limitations 
As this study focused on a community hospital organization on two 
separate units.  The results of this descriptive study apply in this setting but are not 
generalizable. The recent BBI implementation was a small sample size of 90 
patients after the initial roll out of a new practice change. Another limitation of the 
study is its internal validity. The two hospital units have different healthcare 
providers (e.g., hospitalist, independent clinicians) using either SSI or BBI, and 
some might find SSI to be more beneficial than BBI. The hospital had undergone 
new practice changes educating the staff on BBI. Those efforts are ongoing. 
Finally, the study might not have captured the data documentation of glycemic 
control completely, especially when limiting or providing more supplemental 
dextrose or nutritional carbohydrates. 
Recommendations for Future Research 
Future research should use prospective study designs for T2DM patients 
receiving BBI and SSI to understand glycemic control in a hospital setting. In fact, 
studies that use technology of continuous glucose monitoring would offer more 
data on glycemic control. This would include more information on hyperglycemic 
and hypoglycemic events. Future studies could also reveal nurses’ levels of 
comfort and familiarity with BBI. As this study did not include cardiovascular 
patients with T2DM in the telemetry units, conducting a study of this population is 
important as T2DM places this population at high risk for co-morbidity associated 
with poor outcomes if they do not control their glycemic control well (Elliot et.al, 
2016). The use of advanced nurse practice nurses and nurse educators/or those 
who have strong knowledge of and interest in glycemic controls for T2DM 
inpatients can help improve glycemic control. 
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Implications for Nursing Practice 
The results of this study can provide information for nursing. It is important 
that nurses evaluate their current BBI and SSI protocols and, if necessary, review 
the guidelines and workflow processes. Nurses should perform evaluations once 
they have implemented such changes to identify flexibility when modifying 
guidelines and changing workflow as needed. As this study demonstrated, SSI 
achieved better glycemic control than BBI; Therefore, more time is needed for 
evaluating glycemic control and discussing patient outcomes. The use of advanced 
practice nurses and on-site diabetes nurse educators or resources can provide 
support not only for nurses, but also for physicians, hospitalists, external 
providers, by providing inpatient consultation. 
Conclusion 
Providing glycemic control for T2DM patients while hospitalized is 
important. Based on a comparison of average blood glucose levels and the 
estimated HbA1c the SSI group had better glycemic control than the BBI group. It 
may be in this community hospital setting that sliding scale insulin was more 
effective than basal-bolus coverage for glycemic control. More time may be 
needed to effectively evaluate a new practice change. 
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